Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17135075 | 0.78 | HDAC1 (0.55) | NR1H2HDAC1HDAC2GPR119LIPE | |
| SCHEMBL31288397 | 0.78 | HDAC1 (0.55) | NR1H2HDAC1HDAC2GPR119LIPE | |
| SCHEMBL31288417 | 0.78 | HDAC1 (0.55) | NR1H2HDAC1HDAC2GPR119LIPE | |
| SCHEMBL22014823 | 0.77 | MEN1 (0.46) | AOC3SMN1; SMN2 | |
| SCHEMBL19078501 | 0.76 | GPR119 (0.50) | NR1H2HDAC1HDAC2GPR119LIPE | |
| SCHEMBL30040816 | 0.75 | GPR119 (0.50) | NR1H2GPR119PDE10A | |
| SCHEMBL15092041 | 0.75 | GPR119 (0.50) | NR1H2GPR119PDE10A | |
| SCHEMBL25967032 | 0.75 | HDAC1 (0.42) | NR1H2HDAC1HDAC2NAMPTAOC3 | |
| SCHEMBL24693307 | 0.75 | NR1H2 (0.60) | NR1H2HDAC1HDAC2NAMPTGPR119 | |
| SCHEMBL18711408 | 0.75 | NR1H2 (0.60) | NR1H2HDAC1HDAC2NAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | NR1H2 344/4885HDAC1 1487/4885HDAC2 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.